Skip to main content
Top

05-06-2024

Assessing uptake of the core outcome set in anxiety disorder clinical trials: a cross-sectional analysis

Auteurs: Jacob Duncan, Annes Elfar, Kimberly Magana, Garrett Jones, Shaelyn Ward, Trevor Magee, Jay Modi, Kyle Fitzgerald, Griffin Hughes, Alicia Ito Ford, Matt Vassar

Gepubliceerd in: Quality of Life Research

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Excerpt

Anxiety disorders (AD) continue to be a leading cause of health-related burden in 2023, with over 300 million worldwide estimated to be diagnosed [1]. These conditions saw an increase in prevalence due to the global COVID-19 pandemic, with a study by Santomauro et al. showing an increase from 298 to 374 million people affected [2]. The same study estimated 44.5 million years of healthy life lost due to disability or mortality attributable to AD during the pandemic [2]. Furthermore, AD is linked to severe effects on various aspects of quality of life, with one study indicating that individuals diagnosed with AD tend to assess their life circumstances – including health perception, social relationships and home and family life – as notably lower than those unaffected by AD [3]. With the prevalence of these conditions on the rise and their extensive reach across numerous health domains, the call for treatments that are patient-focused and successful cannot be overstated. Standard of care for AD currently include cognitive behavioral therapies, selective serotonin reuptake inhibitors, tricyclic antidepressants, other pharmacologics, and non-pharmacologicals; [4, 5] however, further research is still needed into the optimal use of existing treatments as well as continued search for additional treatments [68]. …
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Javaid, S. F., Hashim, I. J., Hashim, M. J., Stip, E., Samad, M. A., & Ahbabi, A. A. (2023). Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East Current Psychiatry, 30, 44.CrossRef Javaid, S. F., Hashim, I. J., Hashim, M. J., Stip, E., Samad, M. A., & Ahbabi, A. A. (2023). Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East Current Psychiatry, 30, 44.CrossRef
2.
go back to reference Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., et al. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet, 398, 1700–1712.CrossRef Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., et al. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet, 398, 1700–1712.CrossRef
3.
go back to reference Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27, 572–581.CrossRefPubMed Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27, 572–581.CrossRefPubMed
4.
go back to reference Newman, M. G., Castonguay, L. G., Borkovec, T. D., Fisher, A. J., Boswell, J. F., Szkodny, L. E., et al. (2011). A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. Journal of Consulting and Clinical Psychology, 79, 171–181.CrossRefPubMedPubMedCentral Newman, M. G., Castonguay, L. G., Borkovec, T. D., Fisher, A. J., Boswell, J. F., Szkodny, L. E., et al. (2011). A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. Journal of Consulting and Clinical Psychology, 79, 171–181.CrossRefPubMedPubMedCentral
7.
go back to reference Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., et al. (2020). Pharmacotherapy of anxiety disorders: Current and emerging treatment options. Frontiers in Psychiatry, 11, 595584.CrossRefPubMedPubMedCentral Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., et al. (2020). Pharmacotherapy of anxiety disorders: Current and emerging treatment options. Frontiers in Psychiatry, 11, 595584.CrossRefPubMedPubMedCentral
8.
go back to reference Eilertsen, S. E. H., & Eilertsen, T. H. (2023). Why is it so hard to identify (consistent) predictors of treatment outcome in psychotherapy? - clinical and research perspectives. BMC Psychol, 11, 198.CrossRefPubMedPubMedCentral Eilertsen, S. E. H., & Eilertsen, T. H. (2023). Why is it so hard to identify (consistent) predictors of treatment outcome in psychotherapy? - clinical and research perspectives. BMC Psychol, 11, 198.CrossRefPubMedPubMedCentral
9.
go back to reference Kramer, B. S., Wilentz, J., Alexander, D., Burklow, J., Friedman, L. M., Hodes, R. (2006). Getting it right: Being smarter about clinical trials. Plos Medicine. ;3: e144. Kramer, B. S., Wilentz, J., Alexander, D., Burklow, J., Friedman, L. M., Hodes, R. (2006). Getting it right: Being smarter about clinical trials. Plos Medicine. ;3: e144.
12.
go back to reference Mughal, A. Y., Devadas, J., Ardman, E., Levis, B., Go, V. F., & Gaynes, B. N. (2020). A systematic review of validated screening tools for anxiety disorders and PTSD in low to middle income countries. Bmc Psychiatry, 20, 338.CrossRefPubMedPubMedCentral Mughal, A. Y., Devadas, J., Ardman, E., Levis, B., Go, V. F., & Gaynes, B. N. (2020). A systematic review of validated screening tools for anxiety disorders and PTSD in low to middle income countries. Bmc Psychiatry, 20, 338.CrossRefPubMedPubMedCentral
13.
go back to reference Seligman, W. H., Salt, M., la Torre Rosas, A. D., & Das-Gupta, Z. (2019). Unlocking the potential of value-based health care by defining global standard sets of outcome measures that matter to patients with cardiovascular diseases. Eur Heart J Qual Care Clin Outcomes, 5, 92–95.CrossRefPubMed Seligman, W. H., Salt, M., la Torre Rosas, A. D., & Das-Gupta, Z. (2019). Unlocking the potential of value-based health care by defining global standard sets of outcome measures that matter to patients with cardiovascular diseases. Eur Heart J Qual Care Clin Outcomes, 5, 92–95.CrossRefPubMed
14.
go back to reference Obbarius, A., van Maasakkers, L., Baer, L., Clark, D. M., Crocker, A. G., de Beurs, E., et al. (2017). Standardization of health outcomes assessment for depression and anxiety: Recommendations from the ICHOM Depression and anxiety Working Group. Quality of Life Research, 26, 3211–3225.CrossRefPubMedPubMedCentral Obbarius, A., van Maasakkers, L., Baer, L., Clark, D. M., Crocker, A. G., de Beurs, E., et al. (2017). Standardization of health outcomes assessment for depression and anxiety: Recommendations from the ICHOM Depression and anxiety Working Group. Quality of Life Research, 26, 3211–3225.CrossRefPubMedPubMedCentral
16.
go back to reference Kirkham, J. J., Clarke, M., & Williamson, P. R. (2017). A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: Findings from a review of randomised controlled trials of rheumatoid arthritis. Bmj, 357, j2262.CrossRefPubMedPubMedCentral Kirkham, J. J., Clarke, M., & Williamson, P. R. (2017). A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: Findings from a review of randomised controlled trials of rheumatoid arthritis. Bmj, 357, j2262.CrossRefPubMedPubMedCentral
17.
go back to reference Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. Journal of Clinical Epidemiology, 134, 103–112.CrossRefPubMed Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. Journal of Clinical Epidemiology, 134, 103–112.CrossRefPubMed
19.
go back to reference Gopalakrishnan, S., & Ganeshkumar, P. (2013). Systematic reviews and Meta-analysis: Understanding the best evidence in primary Healthcare. J Family Med Prim Care, 2, 9–14.CrossRefPubMedPubMedCentral Gopalakrishnan, S., & Ganeshkumar, P. (2013). Systematic reviews and Meta-analysis: Understanding the best evidence in primary Healthcare. J Family Med Prim Care, 2, 9–14.CrossRefPubMedPubMedCentral
20.
go back to reference Bull, S. A., Hunkeler, E. M., Lee, J. Y., Rowland, C. R., Williamson, T. E., Schwab, J. R., et al. (2002). Discontinuing or switching selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy, 36, 578–584.CrossRefPubMed Bull, S. A., Hunkeler, E. M., Lee, J. Y., Rowland, C. R., Williamson, T. E., Schwab, J. R., et al. (2002). Discontinuing or switching selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy, 36, 578–584.CrossRefPubMed
22.
go back to reference O’Neill, R. T., & Temple, R. (2012). The prevention and treatment of missing data in clinical trials: An FDA perspective on the importance of dealing with it. Clinical Pharmacology and Therapeutics, 91, 550–554.CrossRefPubMed O’Neill, R. T., & Temple, R. (2012). The prevention and treatment of missing data in clinical trials: An FDA perspective on the importance of dealing with it. Clinical Pharmacology and Therapeutics, 91, 550–554.CrossRefPubMed
23.
go back to reference Porter, E., Chambless, D. L., McCarthy, K. S., DeRubeis, R. J., Sharpless, B. A., Barrett, M. S., et al. (2017). Psychometric properties of the Reconstructed Hamilton Depression and anxiety scales. The Journal of Nervous and Mental Disease, 205, 656–664.CrossRefPubMedPubMedCentral Porter, E., Chambless, D. L., McCarthy, K. S., DeRubeis, R. J., Sharpless, B. A., Barrett, M. S., et al. (2017). Psychometric properties of the Reconstructed Hamilton Depression and anxiety scales. The Journal of Nervous and Mental Disease, 205, 656–664.CrossRefPubMedPubMedCentral
24.
go back to reference Koerner, N., Antony, M. M., & Dugas, M. J. (2010). Limitations of the Hamilton Anxiety Rating Scale as a primary outcome measure in randomized, controlled trials of treatments for generalized anxiety disorder. The American Journal of Psychiatry. pp. 103–104; author reply 104–5. Koerner, N., Antony, M. M., & Dugas, M. J. (2010). Limitations of the Hamilton Anxiety Rating Scale as a primary outcome measure in randomized, controlled trials of treatments for generalized anxiety disorder. The American Journal of Psychiatry. pp. 103–104; author reply 104–5.
25.
go back to reference Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166, 1092–1097.CrossRefPubMed Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166, 1092–1097.CrossRefPubMed
26.
go back to reference American Psychiatric Association. (1980). Task Force on nomenclature and statistics. Diagnostic and statistical Manual of Mental disorders. American Psychiatric Association. American Psychiatric Association. (1980). Task Force on nomenclature and statistics. Diagnostic and statistical Manual of Mental disorders. American Psychiatric Association.
27.
go back to reference Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., et al. (2008). Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Medical Care, 46, 266–274.CrossRefPubMed Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., et al. (2008). Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Medical Care, 46, 266–274.CrossRefPubMed
29.
go back to reference Hughes, K. L., Clarke, M., & Williamson, P. R. (2021). A systematic review finds Core Outcome Set uptake varies widely across different areas of health. Journal of Clinical Epidemiology, 129, 114–123.CrossRefPubMedPubMedCentral Hughes, K. L., Clarke, M., & Williamson, P. R. (2021). A systematic review finds Core Outcome Set uptake varies widely across different areas of health. Journal of Clinical Epidemiology, 129, 114–123.CrossRefPubMedPubMedCentral
30.
go back to reference Boric, K., Boric, M., Dosenovic, S., Jelicic Kadic, A., Batinic, M., Cavar, M., et al. (2018). Authors’ lack of awareness and use of core outcome set on postoperative pain in children is hindering comparative effectiveness research. Journal of Comparative Effectiveness Research, 7, 463–470.CrossRefPubMed Boric, K., Boric, M., Dosenovic, S., Jelicic Kadic, A., Batinic, M., Cavar, M., et al. (2018). Authors’ lack of awareness and use of core outcome set on postoperative pain in children is hindering comparative effectiveness research. Journal of Comparative Effectiveness Research, 7, 463–470.CrossRefPubMed
31.
go back to reference Fletcher, J., Sheehan, K. J., & Smith, T. O. (2020). Barriers to uptake of the hip fracture core outcome set: An international survey of 80 hip fracture trialists. Clinical Trials (London, England), 17, 712–716.CrossRefPubMed Fletcher, J., Sheehan, K. J., & Smith, T. O. (2020). Barriers to uptake of the hip fracture core outcome set: An international survey of 80 hip fracture trialists. Clinical Trials (London, England), 17, 712–716.CrossRefPubMed
32.
go back to reference Hughes, K. L., Kirkham, J. J., Clarke, M., & Williamson, P. R. (2019). Assessing the impact of a research funder’s recommendation to consider core outcome sets. PLoS One, 14, e0222418.CrossRefPubMedPubMedCentral Hughes, K. L., Kirkham, J. J., Clarke, M., & Williamson, P. R. (2019). Assessing the impact of a research funder’s recommendation to consider core outcome sets. PLoS One, 14, e0222418.CrossRefPubMedPubMedCentral
33.
go back to reference Kirkham, J. J., Boers, M., Tugwell, P., Clarke, M., & Williamson, P. R. (2013). Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials, 14, 324.CrossRefPubMedPubMedCentral Kirkham, J. J., Boers, M., Tugwell, P., Clarke, M., & Williamson, P. R. (2013). Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials, 14, 324.CrossRefPubMedPubMedCentral
34.
go back to reference Jabonete, F. G. V., & Roxas, R. E. O. (2022). Barriers to research utilization in nursing: A systematic review (2002–2021). SAGE Open Nursing, 8, 23779608221091073.CrossRefPubMedPubMedCentral Jabonete, F. G. V., & Roxas, R. E. O. (2022). Barriers to research utilization in nursing: A systematic review (2002–2021). SAGE Open Nursing, 8, 23779608221091073.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Assessing uptake of the core outcome set in anxiety disorder clinical trials: a cross-sectional analysis
Auteurs
Jacob Duncan
Annes Elfar
Kimberly Magana
Garrett Jones
Shaelyn Ward
Trevor Magee
Jay Modi
Kyle Fitzgerald
Griffin Hughes
Alicia Ito Ford
Matt Vassar
Publicatiedatum
05-06-2024
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-024-03697-x